Leading Experts Discuss Current and Future Immunotherapy for TNBC, Guiding Precision Treatment Development丨2024 Breast Cancer Summer Forum·

Leading Experts Discuss Current and Future Immunotherapy for TNBC, Guiding Precision Treatment Development丨2024 Breast Cancer Summer Forum·

On July 27-28, 2024, the "2024 Breast Cancer Summer Forum·Northern Salon" was grandly held at the Shougang Park in Beijing. The conference adhered to the concept of "learning, absorbing, innovating, and improving" and embraced the tradition of "All directions, Throughout time and across the world, Across all seasons, People of all ages and genders" offering an academic feast in the midsummer. In the era of immunotherapy, triple-negative breast cancer (TNBC) has broken through bottlenecks, achieving survival benefits in both short-term and long-term efficacy. After the TNBC session, Dr. Cuizhi Geng from The Fourth Hospital of Hebei Medical University, Dr. Haibo Wang from The First Clinical Medical College of Qingdao University, Dr. Tao Wang from the Chinese PLA General Hospital, and Dr. Kun Wang from the Guangdong Provincial People's Hospital discussed the present and future of TNBC immunotherapy, guiding the development of precision and individualized immunotherapy.
Dr. Fu Fu Zheng: New Advances in Prostate Cancer Research at the 2024 ASCO Meeting 🌟 | Real-World Exploration and AI Applications in Prostate Cancer Pathology

Dr. Fu Fu Zheng: New Advances in Prostate Cancer Research at the 2024 ASCO Meeting 🌟 | Real-World Exploration and AI Applications in Prostate Cancer Pathology

Prostate cancer is a common malignant tumor of the reproductive system, particularly affecting elderly men. Screening high-risk populations and tailoring treatment plans based on patient characteristics are crucial for improving cure rates and enhancing quality of life. Recently, the 2024 ASCO Annual Meeting unveiled numerous advancements in the treatment of prostate cancer. "Oncology Frontier" invited Dr. Fu Fu Zheng from The First Affiliated Hospital , Sun Yat-sen University to provide an in-depth analysis of these advancements and discuss the latest breakthroughs in prostate cancer. This article summarizes notable real-world research explorations and related poster presentations for readers.
Dr. Fu Fu Zheng: New Advances in Prostate Cancer Research at the 2024 ASCO Meeting (Real-World Exploration and Learning from Others)

Dr. Fu Fu Zheng: New Advances in Prostate Cancer Research at the 2024 ASCO Meeting (Real-World Exploration and Learning from Others)

Prostate cancer is a common malignant tumor of the reproductive system, particularly affecting elderly men. Screening high-risk populations and tailoring treatment plans based on patient characteristics are crucial for improving cure rates and enhancing quality of life. Recently, the 2024 ASCO Annual Meeting unveiled numerous advancements in the treatment of prostate cancer. "Oncology Frontier" invited Dr. Fu Fu Zheng from The First Affiliated Hospital , Sun Yat-sen University to provide an in-depth analysis of these advancements and discuss the latest breakthroughs in prostate cancer. This article summarizes notable real-world research explorations and related poster presentations for readers.
2024 COMB丨Dr. Fei Ma: Metronomic Chemotherapy Combined with Immunotherapy Opens a New Chapter in Breast Cancer Research

2024 COMB丨Dr. Fei Ma: Metronomic Chemotherapy Combined with Immunotherapy Opens a New Chapter in Breast Cancer Research

In the field of breast cancer treatment, innovative therapies are emerging constantly, yet many issues still urgently need to be addressed. Recently, Academician Binghe Xu and Dr. Fei Ma from the Cancer Hospital , Chinese Academy of Medical Sciences and Peking Union Medical College published an article in Nature Medicine titled "Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial." The study introduces the latest progress in metronomic chemotherapy combined with immunotherapy in breast cancer. This research not only provides a new treatment option for breast cancer patients but also reveals the synergistic potential of metronomic chemotherapy and immunotherapy. At the Seventh Tumor Precision Diagnosis and Treatment Conference and the Tenth Breast Cancer Individualized Treatment Conference (2024 COMB), Oncology Frontier invited Dr. Fei Ma to discuss the current state of breast cancer treatment and his team's related articles.
Dr. Fu Fu Zheng: New Advances in Prostate Cancer Research at the 2024 ASCO Meeting (Real-World Exploration and Learning from Others)

Dr. Fu Fu Zheng: New Advances in Prostate Cancer Research at the 2024 ASCO Meeting (Real-World Exploration and Learning from Others)

Prostate cancer is a common malignant tumor of the reproductive system, particularly affecting elderly men. Screening high-risk populations and tailoring treatment plans based on patient characteristics are crucial for improving cure rates and enhancing quality of life. Recently, the 2024 ASCO Annual Meeting unveiled numerous advancements in the treatment of prostate cancer. "Oncology Frontier" invited Dr. Fu Fu Zheng from The First Affiliated Hospital , Sun Yat-sen University to provide an in-depth analysis of these advancements and discuss the latest breakthroughs in prostate cancer. This article summarizes notable real-world research explorations and related poster presentations for readers.
2024 COMB丨Dr. Tao Sun: Progress in HER2+ EBC Treatment—De-escalation Therapy and the Prospects of ctDNA Application

2024 COMB丨Dr. Tao Sun: Progress in HER2+ EBC Treatment—De-escalation Therapy and the Prospects of ctDNA Application

In recent years, the field of breast cancer treatment has seen a series of innovative research advancements, particularly in the treatment of HER2+ early breast cancer (EBC). Strategies such as "de-escalation," "chemotherapy-free," and "precision treatment" have become hot topics. At the 7th Precision Diagnosis and Treatment of Tumors and the 10th Individualized Treatment of Breast Cancer Conference (2024 COMB), Oncology Frontier invited Dr. Tao Sun from Liaoning Cancer Hospital to discuss the latest developments and future directions in HER2+ EBC treatment.
ASCO GU Researcher Speaks丨Professor St-Laurent: Urinary Tumor DNA Detects Minimal Residual Disease, Aiding in Extended Patient Survival

ASCO GU Researcher Speaks丨Professor St-Laurent: Urinary Tumor DNA Detects Minimal Residual Disease, Aiding in Extended Patient Survival

The ASCO-GU 2024, a major event in the field of urologic oncology, was held in San Francisco, USA, showcasing numerous innovative research advancements and discussing future treatment directions for urologic and male reproductive system tumors. For patients with non-muscle invasive bladder cancer (NMIBC) who do not respond to Bacillus Calmette-Guérin (BCG) treatment, there remains a need to find effective tools to detect the risk of recurrence or progression after second-line bladder-sparing treatments. During the conference, Professor Marie-Pier St-Laurent from the University of British Columbia presented the latest advancements in using whole-genome analysis of urinary tumor DNA (utDNA) to identify minimal residual disease (MRD) and quantify genomic changes, sharing in-depth insights in an interview with Oncology Frontier.
EHA International Perspective | Professor Thierry Facon: Major Advances in Multiple Myeloma Treatment—Insights from the IMROZ Study

EHA International Perspective | Professor Thierry Facon: Major Advances in Multiple Myeloma Treatment—Insights from the IMROZ Study

Despite significant improvements in the survival of multiple myeloma (MM) patients over the past two decades, thanks to the emergence of new drugs and therapies, the prognosis for those not eligible for bone marrow transplantation remains relatively poor. Therefore, there is an urgent need to explore new treatment options to improve their outcomes. At the recently held 29th Annual Congress of the European Hematology Association (EHA 2024), Professor Thierry Facon, a member of the International Myeloma Working Group (IMWG) and from the University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France, presented the key findings of the IMROZ study in an oral report. This study explored the efficacy of isatuximab combined with the VRD regimen (Isa-VRD) in treating newly diagnosed MM patients not suitable for transplantation, and the results were published in the New England Journal of Medicine (NEJM) in early June this year. "Oncology Frontier-Hematology Frontier" specially invited Professor Thierry Facon to share the important findings and significance of the IMROZ study at the venue.